Premium
SO09
PERCUTANEOUS RADIOFREQUENCY ABLATION OF LUNG TUMOURS: RESULTS IN FIRST 100 CONSECUTIVE PATIENTS
Author(s) -
Zhu J. C.,
Yan T. D.,
Ng K.,
King J.,
Glenn D.,
Morris D. L.
Publication year - 2007
Publication title -
anz journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.426
H-Index - 70
eISSN - 1445-2197
pISSN - 1445-1433
DOI - 10.1111/j.1445-2197.2007.04131_9.x
Subject(s) - medicine , pneumothorax , radiofrequency ablation , percutaneous , surgery , lung , lung cancer , radiology , complication , ablation
Purpose The study reported our experience with first 100 consecutive patients who underwent radiofrequency ablation (RFA) of their unresectable malignant lung tumours. Methodology From Nov 2000 to Dec 2006, the clinical and treatment‐related information regarding the 100 consecutive patients (58 males, mean age of 65 years) with 240 lung tumours treated by RFA were collected prospectively and reviewed retrospectively. RFA was performed under CT guidance with local anaesthetics and conscious sedation. The patients were followed up with chest CT at regular intervals. Results Five patients had primary lung carcinoma while the remaining patients had pulmonary metastases from extra‐thoracic malignancies, with colorectal cancer being the most common primary site (70%). The mean number of pulmonary lesions ablated was 2.4 per patient; the mean size of lesion was 2.2 cm in diameter. Nineteen patients had repeat RFA for recurrent or residual pulmonary disease. There was no post‐procedural mortality and the overall morbidity rate was 42%. The most common complication was pneumothorax, which occurred in of 31% of procedures (n = 39/127) with only 20 (16%) requiring chest tube placement. After a median follow‐up of 24 months (range 1 to 70 months), 72% of RFA treated lesions did not progress. The overall median disease‐free interval was 13 months, with 1‐, 3‐ and 5‐year disease‐free survival of 55%, 22% and 7% respectively. The overall median survival was 34 months with 1‐, 3‐ and 5‐year‐survival of 85%, 49% and 33% respectively. Conclusion Percutaneous RFA is an emerging therapy with promising results when surgical resection of pulmonary malignancy cannot be performed.